Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 16/20 | 0.33 |
| ▸ | JAK1 | P23458 | 16/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610886 | 1.00 | HCAR1 (0.34) | HCAR1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL16610888 | 1.00 | HCAR1 (0.34) | HCAR1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL16611761 | 0.81 | KDM4E (0.35) | HCAR1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL16623539 | 0.78 | BRD9 (0.32) | HCAR1JAK2JAK1 | |
| SCHEMBL18052592 | 0.76 | BRD9 (0.30) | — | |
| SCHEMBL19216150 | 0.73 | JAK2 (0.43) | JAK2JAK1 | |
| SCHEMBL16610650 | 0.71 | OPRM1 (0.31) | — | |
| SCHEMBL16610648 | 0.71 | OPRM1 (0.31) | — | |
| SCHEMBL25066213 | 0.62 | KCNH2 (0.37) | HCAR1JAK2JAK1JAK3ALDH1A1 | |
| SCHEMBL16332411 | 0.61 | HCAR1 (0.35) | HCAR1JAK2JAK1JAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | HCAR1 2963/4885JAK2 1/4885JAK1 2/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | HCAR1 2963/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.